Heparin-induced thrombocytopenia: Pathogenesis, management, and prevention

Several newer anticoagulants have been used for the management of heparin-induced thrombocytopenia in patients who still require anticoagulation. Two of these agents, the direct thrombin inhibitors lepirudin and argatroban, have been approved by the FDA for HIT management.

Saved in:
Bibliographic Details
Published in:Formulary (Cleveland, Ohio) Ohio), 2001-01, Vol.36 (1), p.26
Main Author: Deitcher, Steven R
Format: Article
Language:English
Subjects:
Antibodies
Anticoagulants
Blood
Blood clots
Blood platelets
Care and treatment
Catheters
Circulatory system
Clinical outcomes
Complications and side effects
Drug therapy
FDA approval
Heparin
Medical disorders
Pathogenesis
Patients
Pharmaceuticals
Pulmonary embolisms
Thrombocytopenia
Thrombosis
Veins & arteries
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several newer anticoagulants have been used for the management of heparin-induced thrombocytopenia in patients who still require anticoagulation. Two of these agents, the direct thrombin inhibitors lepirudin and argatroban, have been approved by the FDA for HIT management.
ISSN:1082-801X
1938-1166